Next Steps After New Frontline Therapy for dMMR Endometrial Cancer
October 27th 2023Matthew Powell, MD, discusses next steps and unmet needs following the phase 3 RUBY/ENGOT-EN6 study and the FDA approval of dostarlimab in combination with chemotherapy for the treatment of patients with mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer.
Watch
Optimizing Treatment Pathways in Non-Metastatic Castration-Resistant Prostate Cancer
October 27th 2023David Morris, MD, FACS, and Benjamin Garmezy, MD, discuss treatment options, including ARPIs like enzalutamide and darolutamide, in nmCRPC, emphasizing the importance of personalized approaches for patient quality of life and outcome improvement.
Watch
Safety and Efficacy of Mosunetuzumab in Elderly Patients With DLBCL
October 26th 2023Adam J. Olszewski, MD, discusses findings from a phase 1b/2 study which evaluated treatment with mosunetuzumab for the treatment of elderly/unfit patients who were previously untreated for their diffuse large B-cell lymphoma.
Watch
Brufsky Recaps PALOMA-2 Study of Palbociclib in Black Patients with aBC
October 25th 2023Adam Brufsky, MD, PhD, FACP, discusses background and next steps of the phase 3 PALOMA-2 study which evaluated palbociclib plus letrozole in patients that identified as Black or Hispanic with advanced breast cancer.
Watch
Reviewing Treatment Decisions for a 66-Year-Old Man With RRMM
October 25th 2023Dr Fonseca discusses the prognosis of a patient with relapsed/refractory multiple myeloma, noting the patient's history with treatments like venetoclax and dexamethasone, and the ultimate decision to switch to talquetamab, a GPRC5D-directed bispecific antibody.
Watch
Available First-Line Systemic Therapy Options for Patients With Metastatic Melanoma
October 25th 2023Hussein Tawbi, MD, PhD, explains that for patients with melanoma without a BRAF mutation, first-line therapies primarily include immunotherapy-based (IO) checkpoint inhibitors, with PD-1 inhibitor combination therapies being the current standard of care.
Watch
Discussing the Investigation of Polatuzumab Combination Therapy in DLBCL
October 24th 2023Elizabeth Lihua Budde, MD, PhD, breaks down the design and baseline characteristics of the phase 3 POLARIX trial that led to the approval of polatuzumab in combination with R-CHP for certain patients with diffuse large B-cell lymphoma.
Watch
Advancements in Immunotherapy and Novel Therapies for Colorectal Cancer
October 24th 2023Shared insight into the latest developments in immunotherapy and novel treatment options for colorectal cancer, including ongoing trials and the pursuit of new targets to enhance the immune response against cancer.
Watch
Personalized Care in CRC: Targeted Therapies and Multidisciplinary Collaboration
October 24th 2023Tracy Proverbs-Singh, MD, and Steven Lee-Kong, MD, explore the forefront of colorectal cancer treatment, featuring targeted therapies, immunotherapy options, and the power of multidisciplinary teamwork.
Watch
Enfortumab Vedotin/Pembrolizumab Shows Encouraging Survival Data in mUC
October 22nd 2023Thomas Powles, MD, MBBS, MRCP, discusses findings from the phase 3 EV-302 clinical trial of enfortumab vedotin-ejfv with pembrolizumab vs chemotherapy for the treatment of patients with previously untreated locally advanced or metastatic urothelial cancer.
Watch
Future Landscape: Collaboration for Patients With Relapsed/Refractory Multiple Myeloma
October 20th 2023Discover how the treatment landscape for relapsed/refractory myeloma is evolving through collaboration between academic centers and community oncologists, offering patients access to innovative therapies and clinical trials.
Watch